Stanford RNA Urine Test Detects Bladder Cancer More Accurately Than Cystoscopy

The test sequences fragmented RNA shed by tumor cells into urine to capture active gene expression rather than mutations, bypassing field-effect mutations common in normal bladder lining that confound DNA assays. Researchers adapted sequencing methods to handle low-abundance RNA and demonstrated detection of cancer presence, post-treatment residual disease, and likelihood of response to BCG versus chemotherapy or checkpoint inhibitors without needing matched tumor tissue.

This builds directly on the same group’s CAPP-Seq DNA liquid-biopsy platform previously validated in lung cancer and lymphoma, but shifts to RNA to solve bladder-specific problems. The approach could reduce reliance on cystoscopy, which misses up to 30% of tumors and requires repeated procedures every three months in high-risk surveillance, while enabling earlier personalization of intravesical therapy.

Observational data from the current cohort show improved sensitivity and specificity over standard cytology and imaging, yet lack randomization or long-term outcome endpoints. Remaining questions center on performance across stages, ethnic groups, and post-BCG settings, plus assay reproducibility in routine clinical labs.

Larger prospective multicenter trials are required to establish clinical utility and regulatory clearance before guideline incorporation.